Advances in the Management of Bladder and Kidney Cancer

A MULTIDISCIPLINARY APPROACH

mskcc.org/urologycourse
The course objective is to advance and disseminate knowledge of new approaches to the multidisciplinary management of bladder and kidney cancer. This will include insights into the ongoing cancer research in the field and at MSK.

MSK Course Directors

James A. Eastham, MD, FACS
Chief, Urology Service
Peter T. Scardino Chair in Oncology

Jonathan E. Rosenberg, MD
Chief, Genitourinary Medical Oncology Service
Division of Solid Tumor Oncology
Enno W. Ercklentz Chair

MSK Program Planning Committee

Bernard H. Bochner, MD, FACS
Attending Surgeon
Urology Service
Sir Murray Brennan Chair in Surgery

Abraham A. Hakimi, MD
Assistant Attending Surgeon
Urology Service

Gopakumar V. Iyer, MD
Assistant Attending
Bladder Cancer Section Head
Genitourinary Oncology Service

Martin H. Voss, MD
Assistant Attending
Genitourinary Oncology Service

The aim of this program, presented by faculty from Memorial Sloan Kettering (MSK) and invited speakers, is to highlight new developments in the multidisciplinary management of bladder and kidney cancer. This will include insights into the ongoing cancer research in the field and at MSK.

The course objective is to advance and disseminate knowledge of new approaches to the multidisciplinary management of bladder and kidney cancer.

The program will include comprehensive state-of-the art lectures and discussions encouraging the exchange of ideas between faculty (radiologists, pathologists, surgeons, radiation oncologists, and medical oncologists) and the audience. Discussions will center on the multidisciplinary management of bladder and kidney cancer.

Educational Objectives

• To present a multidisciplinary approach to the management of bladder and kidney cancer including surgery, medical oncology, and radiation therapy.
• To advance and disseminate knowledge of new approaches to the multidisciplinary management of bladder and kidney cancer

Target Audience

The intended audience includes urologists, urologic-oncologists, medical oncologists, radiation oncologists, pathologists, radiologists, and allied health professions.

Live Simulcast Available

We are pleased to offer a live simulcast option for this course. CME and ABIM MOC credit is offered for the live simulcast and active participation is required throughout the course.

mskcc.org/urologycourse
COURSE FACULTY

Invited Course Faculty

Arjun Balar, MD
Associate Professor of Medicine
Director, Genitourinary Medical Oncology Program
NYU Perlmutter Cancer Center

James M. McKiernan, MD
Chairman, Urologist-in-Chief
Department of Urology
Columbia University/NewYork-Presbyterian

Brian Shuch, MD
Associate Professor of Urology
Kidney Cancer Program Director
Department of Urology
UCLA School of Medicine

R. Houston Thompson, MD
Professor of Urology
Department of Urology
Mayo Clinic

Keynote Speaker

Brian I. Rini, MD, FACP
Professor of Medicine
Lerner College of Medicine Leader, GU Program
Director, Experimental Therapeutics Fellowship Program
Hematology and Oncology & Glickman Urological and Kidney Institute
Cleveland Clinic Taussig Cancer Institute

MSK Course Faculty

Oguz Akin, MD
Attending Radiologist
Director of Body MRI
Department of Radiology

Hikmat Al-Ahmadie, MD
Associate Attending Pathologist
Genitourinary Pathology

Charlotte E. Ariyan, MD, PhD
Associate Attending Surgeon
Gastric and Mixed Tumor Service

Dean F. Bajorin, MD
Attending Physician
Frederick R. Adler Senior Faculty Chair
Genitourinary Oncology Service
Professor of Medicine, Weill Cornell Medical College

Bernard H. Bochner, MD, FACS
Attending Surgeon
Urology Service
Sir Murray Brennan Chair in Surgery

Eugene K. Cha, MD
Assistant Attending Surgeon
Urology Service

Timothy A. Chan, MD, PhD
Vice Chair and Attending Physician
Department of Radiation Oncology
Director, Division of Translational Oncology
Director, Immuno-oncogenomics and Precision Oncology Platform
Member, Human Oncology and Pathogenesis Program

Yingbei Chen, MD, PhD
Associate Attending Pathologist
Genitourinary Pathology

Marie Carlo, MD
Assistant Attending
Genitourinary Oncology Service

Jonathan A. Coleman, MD
Associate Attending Surgeon
Urology Service

S. Machele Donat, MD, FACS
Attending Surgeon
Urology Service

Jeremy C. Durack, MD, FACS
Attending Radiologist
Interventional Radiology Service

James A. Eastham, MD, FACS
Chief, Urology Service
Peter T. Scardino Chair in Oncology

Darren R. Feldman, MD
Associate Attending
Genitourinary Oncology Service

Samuel A. Funt, MD
Assistant Attending
Genitourinary Oncology Service

Alvin C. Goh, MD
Associate Attending Surgeon
Urology Service

Abraham A. Hakimi, MD
Assistant Attending Surgeon
Urology Service

Harry W. Herr, MD
Attending Surgeon
Urology Service

Gopakumar V. Iyer, MD
Assistant Attending
Bladder Cancer Section Head
Genitourinary Oncology Service

Marisa A. Kollmeier, MD
Associate Attending Physician
Chair, Radiation Oncology Quality Assurance
Brachytherapy Service

Chung-Han Lee, MD, PhD
Assistant Attending
Genitourinary Oncology Service

Robert J. Motzer, MD
Attending
Genitourinary Oncology Service

Eugene Pietzak, MD
Assistant Attending Surgeon
Urology Service
Brachytherapy Service

Paul Russo, MD
Attending Surgeon
Urology Service
Professor of Urology, Weill Cornell College of Medicine

Jonathan E. Rosenberg, MD
Chief, Genitourinary Medical Oncology Service
Division of Solid Tumor Oncology
Ennio W. Ecklerenz Chair

Min Yuen Teo, MD
Assistant Attending
Genitourinary Oncology Service

Martin H. Voss, MD
Assistant Attending
Genitourinary Oncology Service

Join the conversation:
#MSKurologyCME
@MSKCME
### Thursday, October 24

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00</td>
<td>Lunch and Registration</td>
<td></td>
</tr>
<tr>
<td>12:50</td>
<td>Welcome and Opening Remarks</td>
<td>Jonathan E. Rosenberg, MD</td>
</tr>
<tr>
<td></td>
<td>**BLADDER</td>
<td>Clinical and Molecular Characteristics of NMIBC**</td>
</tr>
<tr>
<td></td>
<td><strong>MODERATOR:</strong> Eugene K. Cha, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Updates on Natural History of High Risk NMIBC</td>
<td>Bernard H. Bochner, MD, FACS</td>
</tr>
<tr>
<td></td>
<td>NMIBC Molecular Biology</td>
<td>Eugene Pietzak, MD</td>
</tr>
<tr>
<td></td>
<td>New Detection Technologies: Blue Light and NBI</td>
<td>James M. Mckiernan, MD</td>
</tr>
<tr>
<td>1:00</td>
<td>**BLADDER</td>
<td>Standard Management and Novel Therapies for NMIBC**</td>
</tr>
<tr>
<td></td>
<td><strong>MODERATOR:</strong> Bernard H. Bochner, MD, FACS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Management of BCG - Unresponsive NMIBC</td>
<td>Eugene K. Cha, MD</td>
</tr>
<tr>
<td></td>
<td>Role of Checkpoint Inhibitors for NMIBC</td>
<td>Dean F. Bajorin, MD</td>
</tr>
<tr>
<td></td>
<td>Case Discussions</td>
<td></td>
</tr>
<tr>
<td></td>
<td>BCG Shortage; Optimal BCG, Selection for Early Cystectomy;</td>
<td>Harry W. Herr, MD</td>
</tr>
<tr>
<td></td>
<td>Persistent Positive Cytology (Natural History, Surveillance vs. Therapy)</td>
<td>Dean F. Bajorin, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Eugene K. Cha, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>James M. Mckiernan, MD</td>
</tr>
<tr>
<td></td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>3:00</td>
<td>**KIDNEY</td>
<td>Controversies and Management of Small Renal Masses**</td>
</tr>
<tr>
<td></td>
<td><strong>MODERATOR:</strong> Jonathan A. Coleman, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SRM - Epidemiology and Treatment Molecular (Overtreatment)</td>
<td>Abraham A. Hakimi, MD</td>
</tr>
<tr>
<td></td>
<td>Biopsy</td>
<td>Yingbei Chen, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>Ablation</td>
<td>Jeremy C. Durack, MD, MD</td>
</tr>
<tr>
<td></td>
<td>Surveillance and Genomics</td>
<td>Brian Shuch, MD</td>
</tr>
<tr>
<td></td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>7:30</td>
<td>Breakfast</td>
<td></td>
</tr>
<tr>
<td>8:00</td>
<td>**KIDNEY</td>
<td>Management of Locally Advanced Renal Cell Carcinoma**</td>
</tr>
<tr>
<td></td>
<td><strong>MODERATOR:</strong> Abraham A. Hakimi, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Partial vs Radical for &gt;= pT1b</td>
<td>Paul Russo, MD</td>
</tr>
<tr>
<td></td>
<td>LN Dissection</td>
<td>R. Houston Thompson, MD</td>
</tr>
<tr>
<td></td>
<td>Perioperative Therapy in the Non-metastatic Setting</td>
<td>Martin H. Voss, MD</td>
</tr>
<tr>
<td></td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>10:05</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>**KIDNEY</td>
<td>Controversies and Management of Small Renal Masses**</td>
</tr>
<tr>
<td></td>
<td><strong>MODERATOR:</strong> Abraham A. Hakimi, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Novel Imaging in RCC</td>
<td>Oguz Akın, MD</td>
</tr>
<tr>
<td></td>
<td>Case Discussions</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Multifocal Renal Masses, SRM in Elderly</td>
<td>Abraham A. Hakimi, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jonathan A. Coleman, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Paul Russo, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Brian Shuch, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jeremy C. Durack, MD, MD</td>
</tr>
<tr>
<td></td>
<td>Adjourn</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Networking Reception</strong></td>
<td>Join the course faculty for a networking reception immediately</td>
</tr>
<tr>
<td></td>
<td></td>
<td>following the conclusion of day one from 5:00-6:30 PM at Zuckerman</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Research center. Hors d’oeuvres and refreshments will be served.</td>
</tr>
</tbody>
</table>

### Friday, October 25

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30</td>
<td>Breakfast</td>
<td></td>
</tr>
<tr>
<td>8:00</td>
<td><strong>Keynote Address &amp; Department of Medicine Grand Rounds</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Emerging Paradigms in the Upfront Management of Metastatic Kidney Cancer</td>
<td>Brian I. Rini, MD, FACP</td>
</tr>
<tr>
<td></td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>9:15</td>
<td>**KIDNEY</td>
<td>Management of Locally Advanced Renal Cell Carcinoma**</td>
</tr>
<tr>
<td></td>
<td><strong>MODERATOR:</strong> Abraham A. Hakimi, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Neoadjuvant Therapy for Cis-eligible Patients</td>
<td>Gopakumar V. Iyer, MD</td>
</tr>
<tr>
<td></td>
<td>(Cisplatin-based Chemotherapy, IO+Chemotherapy Trials)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Adjuvant Therapy for MIBC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Including Data on Standard and Novel Therapies)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Importance of Germline Mutations in Urothelial Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:45</td>
<td>**BLADDER</td>
<td>Surgical Management of MIBC: Robotics and Radical Cystectomy**</td>
</tr>
<tr>
<td></td>
<td><strong>MODERATOR:</strong> Jonathan A. Coleman, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Open vs Robotic Surgery for MIBC: Update of Current Data</td>
<td></td>
</tr>
<tr>
<td></td>
<td>RARC: How to. Tips and Tricks</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>Lunch</td>
<td></td>
</tr>
</tbody>
</table>
## KIDNEY | RCC Management in the Metastatic Setting  
**Moderator:** Martin H. Voss, MD  
**2nd Line Therapy and Beyond:**  
Approved Agents and Their Application in the Post-IO Space  
Chung-Han Lee, MD, PhD  
**1:30 PM**  
**Break**  
2:50 PM

## Principles in Practice: Immuno-Oncology Drugs in Bladder and Kidney Cancers  
**Moderator:** Gopakumar V. Iyer, MD  
**Biologic Principles Behind Immune-oncology**  
Timothy A. Chan, MD, PhD  
**8:00 AM**  
**Surgical Safety in IO Treated Patients**  
Charlotte E. Ariyan, MD, PhD  
**8:20 AM**  
**IO Tox Management**  
Samuel A. Funt, MD  
**8:40 AM**

## Bladder | Molecular Principles of Bladder Cancer  
**Moderator:** Dean F. Bajorin, MD  
**Molecular Biology of MIBC - Role in Bladder Preservation**  
Gopakumar V. Iyer, MD  
**3:00 PM**  
**Trimodal Therapy for MIBC**  
Marisa A. Kollmeier, MD  
**3:20 PM**  
**Case Discussions**  
Bladder Preservation  
Gopakumar V. Iyer, MD  
Marisa A. Kollmeier, MD  
Harry W. Herr, MD  
**3:35 PM**

## KIDNEY | Multidisciplinary Approaches to Metastatic Kidney Cancers  
**Moderator:** Paul Russo, MD  
**Cytoreduction + Metastasectomy**  
Paul Russo, MD  
**9:00 AM**  
**Case Discussions**  
Paul Russo, MD  
Marie Carlo, MD  
Darren R. Feldman, MD  
**9:40 AM**

## Systemic Therapy for Metastatic Non-clear Cell RCC  
Darren R. Feldman, MD  
**10:00 AM**

## Emerging Regimens for Metastatic RCC  
Chung-Han Lee, MD, PhD  
**10:20 AM**

## Break  
2:50 PM

## Breakfast  
7:30 AM

## Saturday, October 26

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 AM</td>
<td>Breakfast</td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td>Principles in Practice: Immuno-Oncology Drugs in Bladder and Kidney Cancers</td>
<td>Gopakumar V. Iyer, MD</td>
</tr>
<tr>
<td>8:20 AM</td>
<td>Surgical Safety in IO Treated Patients</td>
<td>Charlotte E. Ariyan, MD</td>
</tr>
<tr>
<td>8:40 AM</td>
<td>IO Tox Management</td>
<td>Samuel A. Funt, MD</td>
</tr>
<tr>
<td>9:00 AM</td>
<td>Cytoreduction + Metastasectomy</td>
<td>Paul Russo, MD</td>
</tr>
<tr>
<td>9:40 AM</td>
<td>Case Discussions</td>
<td>Paul Russo, MD</td>
</tr>
<tr>
<td>9:40 AM</td>
<td>Familial Predisposition Syndromes and Germline Testing in RCC</td>
<td>Marie Carlo, MD</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Systemic Therapy for Metastatic Non-clear Cell RCC</td>
<td>Darren R. Feldman, MD</td>
</tr>
<tr>
<td>10:20 AM</td>
<td>Emerging Regimens for Metastatic RCC</td>
<td>Chung-Han Lee, MD</td>
</tr>
<tr>
<td>10:30 AM</td>
<td>IO Therapy for Advanced Bladder Cancer; Data for IO in the 1st Line Metastatic Setting</td>
<td>Jonathan E. Rosenberg, MD</td>
</tr>
<tr>
<td>10:50 AM</td>
<td>Predictive Biomarkers and Novel Metastatic Options (ADC, FGFR3 Inhibition)</td>
<td>Arjun Balar, MD</td>
</tr>
</tbody>
</table>

## Break  
2:50 PM

## BLADDER | The Role of Bladder Preservation in MIBC  
**Moderator:** Dean F. Bajorin, MD  
**2nd Line Therapy and Beyond:**  
Approved Agents and Their Application in the Post-IO Space  
Chung-Han Lee, MD, PhD  
**3:00 PM**  
**Molecular Biology of MIBC - Role in Bladder Preservation**  
Gopakumar V. Iyer, MD  
**3:20 PM**  
**Trimodal Therapy for MIBC**  
Marisa A. Kollmeier, MD  
**3:35 PM**  
**Case Discussions**  
Bladder Preservation  
Gopakumar V. Iyer, MD  
Marisa A. Kollmeier, MD  
Harry W. Herr, MD  
**3:35 AM**

## Lower Urinary Tract  
**Moderator:** Dean F. Bajorin, MD  
**Management of Metastatic Bladder Cancer in the Immunotherapy Era**  
**Moderator:** Dean F. Bajorin, MD  
**IO Therapy for Advanced Bladder Cancer:**  
Data for IO in the 1st Line Metastatic Setting  
Jonathan E. Rosenberg, MD  
**10:30 AM**  
**Predictive Biomarkers and Novel Metastatic Options (ADC, FGFR3 Inhibition)**  
Arjun Balar, MD  
**11:10 AM**

## Symposia Adjourn  
11:30 AM

---

**Live Simulcast Available**  
Unable to attend this course in person? We are pleased to offer a live simulcast option for this course. CME and ABIM MOC credit is offered for the live simulcast and pre-registration is required.  
Visit the course website for details: [mskcc.org/urologycourse](http://mskcc.org/urologycourse)
### Registration Fees

<table>
<thead>
<tr>
<th>Category</th>
<th>Early*</th>
<th>General</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians (MDs, PhDs &amp; DOs)</td>
<td>$500</td>
<td>$600</td>
</tr>
<tr>
<td>Advanced Practice Providers</td>
<td>$350</td>
<td>$450</td>
</tr>
<tr>
<td>Residents, Fellows, Nurses &amp; Other Healthcare Providers</td>
<td>$200</td>
<td>$300</td>
</tr>
<tr>
<td>Industry Professionals**</td>
<td>$900</td>
<td>$1,100</td>
</tr>
<tr>
<td>Live Simulcast</td>
<td>--</td>
<td>$800</td>
</tr>
</tbody>
</table>

Register online: [mskcc.org/urologycourse](http://mskcc.org/urologycourse)

Course registration includes continental breakfast, lunch, and refreshment breaks. Please contact cme@mskcc.org at least one week prior to the course if you have any special dietary requests or require any specific accommodations.

- MSK CME offers a discounted rate for MSK Alumni, MSK Cancer Alliance and Cancer Care Partners. If you are a member of one of these groups, please contact cme@mskcc.org for more information.
- MSK employee registration is complimentary. However, you must complete course registration in order to attend this course.

*Early registration rates expire August 23, 2019.

**Industry professionals may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities.

### Course Location

Memorial Sloan Kettering Cancer Center
Zuckerman Research Center
417 East 68th Street
New York, NY

### Accommodations

MSK has negotiated special rates and amenities at select hotels in Manhattan. For information on hotels in the vicinity of MSK with discounted rates, visit: [mskcc.org/cme](http://mskcc.org/cme)

### Contact

Memorial Sloan Kettering Cancer Center
Office of Continuing Medical Education
w: mskcc.org/cme
e: cme@mskcc.org

---

**Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.**

### AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of 16.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 16.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

### Faculty Disclosure

It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it provides as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity provided by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unapproved use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.
Advances in the Management of Bladder and Kidney Cancer

A MULTIDISCIPLINARY APPROACH

Memorial Sloan Kettering Cancer Center